Avaliação da resposta citotóxica no tratamento do tumor venéreo transmissível em cães através da utilização de Bleomicina ou Vincristina

• Autor(a) principal: Huppes, Rafael Ricardo
• Data de Publicação: 2011
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/683
• topic: Oncologia - Cães; Quimiorresistência; Citotoxicidade; Subcutâneo; Intratumoral; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::PATOLOGIA ANIMAL

Considering the increase in chemoresistance due to the use of vincristine sulfate in the treatment of canine transmissible venereal tumor (TVT), new therapeutic options must be evaluated to combat this neoplasm. The objective of this work was to evaluate the efficacy of bleomycin sulfate, subcutaneously or intratumorally, in the treatment of this tumor, comparing the results achieved with those obtained from the use of vincristine sulfate. For this purpose, 15 dogs with confirmed TVT lesion through cyto and / or histopathological exams were selected, and these were distributed in three groups of five animals. Control group (G1) patients received vincristine sulfate at a dose of 0.75 mg / m² / IV, patients in group G2 underwent chemotherapy using bleomycin sulfate, intratumorally, at a dose of 0.4 IU / Kg, while dogs in the G3 group received bleomycin sulfate, at a dose of 0.4 IU / Kg, subcutaneously. In patients in the G1 group, cytoreduction occurred gradually over the sessions, and in four of the five dogs there was complete remission after the fifth session of antineoplastic chemotherapy, resulting in a statistically significant difference (p <0.05) when compared with the results of the groups. G3. The dogs in the G3 group, on the other hand, presented cytoreduction only after the first session, this was not observed in the second, third and fourth sessions, when the tumors remained stable, growing again in the fifth and sixth application. The dogs in the G2 group showed an important remission after the first session, however, in the second, third and fourth sessions the tumors remained stable and after the fifth and sixth applications they showed a slight regression. The best results, without a doubt, were observed with the administration of vincristine sulfate, however, new studies should be carried out to improve the efficacy of bleomycin sulfate in the treatment of TVT. An option that should be better studied is the use of intratumoral bleomycin in cases of TVT that have already been treated and presented resistance to the use of vincristine sulfate.